R ecent advancement in the treatment of renal tumor, especially Wilms tumor, has resulted in a much better prognosis. Overall cure rate was as high as 90% in some reports. Long-term outcomes, especially renal, are still a concern as combinations of chemotherapy, abdominal radiation, and unilateral nephrectomy are often needed. 1 Studies from the National Wilms Tumor Study Group reported a low incidence of renal failure in children with unilateral tumor. They also found that children with WAGR syndrome or associated genitourinary tract anomalies are at a higher risk of impaired renal function. 2, 3 Another study from North America showed that cumulative incidence of end-stage renal disease 20 years after Wilms tumor diagnosis was only 0.7%. Characteristics associated with a WT1 etiology (early onset, stromal predominant histology, intralobar nephrogenic rests) markedly increased the risk of end-stage renal disease. 4 In contrast, a study in the United Kingdom revealed an overall incidence of renal dysfunction in 32% of Wilms tumor survivors, including 19% with low glomerular filtration rate (GFR), 11% with hypertension, and 9% with increased urinary albumin excretion. One of the 53 patients in the study had hemihypertrophy but otherwise there were no other congenital abnormalities. 5 A study from Poland revealed increased urine albumin and b-2-microglobulin in 22% and 9.4% of Wilms tumor survivors, respectively. Ultrasound signs of kidney damage were reported in 43%. Chronic kidney disease (CKD) stage 1 and 2 were found in 56.25% and 43.75%, respectively. 6 The Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand is a tertiary care center and university hospital. The hospital catered for 100 to 120 childhood cancer cases per year with renal tumor being one of our top 10 most common cancers.
The objective of this study was to determine the longterm outcome of renal tumor in children attending our center. The results of this study may be applicable to many developing countries and the general Asian population.
METHODS
Medical records of all patients younger than 15 years diagnosed with renal tumor at Siriraj Hospital, Bangkok, Thailand during 1996 to 2007 were reviewed.
Clinical stage of renal tumor patients was classified and treatment protocol was devised according to the National Wilms Tumor Study-5. 7 All patients underwent an initial nephrectomy as a basic principle; preoperative chemotherapy was considered for those whom the tumor seemed unresectable or bilateral. Oncopathologists reviewed the histology, and the patients received postoperative chemotherapy with or without radiation therapy according to pathologic diagnosis and clinical stage. After treatment completion, patients were seen by an oncologist every 6 to 8 weeks in the first year and then every 3 months for 2 years. They attended the clinic every 6 months until the end of 5 years and then annually afterward. Demographic data of the patients, treatment received, and outcome of treatment and complications were recorded.
Urine samples were tested for protein and glucose by URISYS (Roche Diagnostics GmbH) as well as microscopically. GFR was estimated using Schwartz formula. 8 Estimated GFR was recorded at diagnosis, 1 year after chemotherapy, and at last follow-up. Acute renal failure was defined according to the modified pediatric RIFLE criteria as a decrease in estimated GFR >75% or a 3-fold rise in baseline serum creatinine or the need for renal replacement therapy. 9 CKD was defined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative. CKD was categorized into 5 different stages, from stage 1 (mild disease) to stage 5 (kidney failure). 10 Statistical analysis was performed using SPSS 11.5 (Chicago, IL). Descriptive analysis (mean ± SD) was performed for baseline parameters. The w 2 test was used to compare other parameters. A P value <0.05 was considered significant. Five-year overall survival and 5-year disease-free survival were analyzed using the Kaplan-Meier Survival estimate.
This study was approved by the Siriraj Ethics Committee.
RESULTS
Renal tumor was diagnosed in 30 patients during 1996 to 2007. Mean age at diagnosis was 36 ± 24 months; male to female ratio was 1.7:1. Most of the patients (66.6%) were from Bangkok and surrounding areas. Clinical manifestations included abdominal mass (96.7%), hypertension (40.0%), abdominal pain (36.7%), hematuria (26.7%), postrenal obstruction (16.7%), ascites (13.3%), inferior vena cava thrombosis (13.3%), and proteinuria (13.3%). Mean estimated GFR at diagnosis was 129 mL/min/ 1.73 m 2 . Eight patients (26.7%) had other congenital anomalies. Two patients had Denys-Drash malformations, 1 had WAGR, 1 had Dandy-Walker malformation, and 4 had genitourinary anomalies, that is, horse-shoe kidney and undescended testis. Mean age at diagnosis for this group of patients was 32 months.
Unilateral nephrectomy was performed in 29 patients (96.7%), mostly before chemotherapy. Renal biopsy was performed before chemotherapy in 1 patient with bilateral tumor. Five patients with a huge mass involving inferior vena cava and postrenal obstruction received chemotherapy before nephrectomy. Postoperatively, massive bleeding occurred in 2 patients, gut obstruction in 2 patients, and transient poor perfusion of left foot in 1 patient. Most patients (90%) had Wilms tumor with favorable histology in 80%; anaplastic and rhabdoid tumor each was reported in 3 patients (10%).
Staging of the disease revealed stage 1 in 3 patients (10.0%), stage 2 in 11 patients (36.7%), stage 3 in 8 patients (26.7%), and stage 4 in 5 patients (16.7%). In 5 patients with stage 4 disease, 3 patients had lung metastasis alone, 1 patient had lung, liver, and bone metastasis, and another had bone and lymph node metastasis. Three patients (10.0%) had bilateral tumor (stage 5) at diagnosis; one of these had WAGR syndrome and another one had DenysDrash malformations (Table 1) .
All patients received chemotherapy according to the National Wilms Tumor Study-5. 7 Ifosfamide-carboplatinetoposide (ICE) protocol was needed in 11 patients because of disease progression; one of these had Denys-Drash malformations and another one had horse-shoe kidney. Thirteen patients (43.3%) received radiation therapy, including whole abdominal irradiation in 5, tumor bed irradiation in 4, chest irradiation in 3, and lymph node irradiation in 1 patient. Acute complications included febrile neutropenia (44.4%), hypokalemia (37.0%), hyponatremia (29.6%), Fanconi syndrome (11.1%), urinary tract infection (10.0%), and acute renal failure (7.4%).
Mean follow-up time was 57.2 months (2.0 to 167.6 mo). One patient was lost to follow-up, and 2 patients were referred to their local hospitals for palliative care. Ten patients (33.3%) died from progressive disease. Three of them had rhabdoid histology and another 2 patients had anaplastic histology. Five-year overall survival using the Kaplan-Meier survival estimate was 69.7% (95% confidence interval [CI], 49.7-82.9). During follow-up, 6 patients had recurrence of renal tumor resulting in a 5-year disease-free survival of 63.0% (95% CI, 42.1-78.1). One patient had autologous peripheral blood stem cell transplantation after relapse of disease in the sacrum. The histology of relapse tumor was reviewed and confirmed to be Wilms tumor (Table 2 ). If those with rhabdoid histology were excluded, overall patient survival and disease-free survival were 77.4% (95% CI, 56.4-89.2) and 70.8% (95% CI, 48.3-84.9), respectively.
At last follow-up, 2 patients (7.4%) developed CKD. Patient 1 also had proximal tubular acidosis. This patient was 32 months old at diagnosis. He was diagnosed with stage 2 tumor with favorable histology and was hypertensive at diagnosis. After 1½ years of standard chemotherapy, he had disease recurrence with pulmonary and bone metastasis, and ICE protocol together with radiation were given. Acute renal failure was noted during treatment. Autologous peripheral blood stem cell transplantation, which consisted of busulfan-melphalan-topotecan conditioning regimen, was also performed afterward with good results. His estimated GFR at last follow-up (48 mo after diagnosis) was 60.5 mL/min/1.73 m 2 (CKD stage 2). Patient 2 was 48 months old at diagnosis. He was diagnosed with stage 2 tumor with favorable histology and also had DenysDrash malformations. Seven months after standard chemotherapy, the tumor recurred. He received ICE protocol and abdominal radiation, and acute renal failure was also noted during treatment. His estimated GFR at last follow-up (44 mo after diagnosis) was 54.4 mL/min/1.73 m 2 (CKD stage 3).
Of the 12 patients with hypertension at diagnosis, blood pressure levels returned to normal shortly after surgery in 3. Antihypertensive medications were needed in 9 patients (30%) for a median duration of 164 days (49 to 1360 d). None of the 30 patients had proteinuria or hematuria at last follow-up. Mean estimated GFR were 138, 104, and 119 mL/min/1.73 m 2 at diagnosis, 1 year after treatment, and at last follow-up, respectively. No difference was found among mean estimated GFR at diagnosis, 1 year after treatment, and at last follow-up (P = 0.333 and 0.254).
DISCUSSION
The incidence of childhood renal cancer worldwide was approximately 8 per million and almost all were Wilms tumor. Most of the patients had unilateral disease and were sporadic cases. Bilateral disease, defined as stage 5, was noted in 4% to 13% of cases. The tumor often occurred in children younger than 5 years, without male or female preponderance. 1, 11, 12 About 10% to 15% of these patients were associated with recognized malformations such as WAGR syndrome, Denys-Drash syndrome, hypospadias, and other genitourinary tract anomalies. 13 Patients with WAGR were reported to have a 50% chance of end-stage renal disease, 20 years after treatment. 14 Another study in nearly 6000 patients with Wilms tumor revealed cumulative risks of renal failure at 20 years from diagnosis in DenysDrash and Wilms tumor-Aniridia syndromes of 62% and 38%, respectively. Male patients with congenital genitourinary tract anomalies had a risk of 11%. Patients with bilateral disease had a risk of 6%. Those with unilateral disease and without congenital anomalies had a renal failure risk of <1%. The authors suggested the possibility of degradation in the phenotypes associated with different WT1 mutations. Five patients from the 28 Wilms tumor patients without WAGR syndrome, Denys-Drash syndrome, or genitourinary tract anomalies who developed renal failure were attributable to radiation nephritis and another 5 patients in this group received ifosfamide. 15 Another study showed a cumulative incidence of end-stage renal disease 20 years after Wilms tumor diagnosis of 0.7%. Risk factors for end-stage renal disease in non-WT1 syndromic Wilms tumor included stromal predominant histology, intralobar rests, and patients younger than 24 months at diagnosis. 4 This study revealed a different demographic data in Thai patients, that is, a higher incidence of associated anomalies (26.7%) as compared with 10% in the study by Vujanic 16 and a higher percentage of the patients (53.4%) with stage 3 or more at diagnosis as compared with 28.1% to 34.0% in other studies. 5, 17 A study of 210 pediatric renal tumor cases from Japan revealed 5-year survivals of 91.1%, 74.5%, and 22.2% for patients with Wilms tumor, clear cell sarcoma of the kidney, and rhabdoid tumor of the kidney, respectively. Only 2 patients developed end-stage renal disease. 17 The lower overall 5-year patient survival (69.7%) in this study may be because of advance stage, as more than half of the patients had stage 3 or more. These patients needed more aggressive management resulting in more complications and higher mortality rate. Genetic difference may also play an important role in this disease but we have not studied this in our population. Data from other developing countries, especially Asian children, is needed to clarify this observation. These factors may also be the cause of a high incidence (7.4%) of CKD after treatment. In contrast, the incidence of CKD in this study is lower than the one reported by Stefanowicz et al. 6 This may be partly because of their longer follow-up period (mean = 9.3 y) and detailed renal damage markers included. No data on markers for early renal impairment, such as cystatin C and b-2-microglobulin, and ultrasound signs of kidney damages were available in this study; therefore, our incidence of renal impairment may be underestimated. However, all our patients except for 2 patients with CKD did not have signs or symptoms of renal impairment, including abnormal blood for kidney function (BUN/creatinine) and urine examination. One of the patients with CKD in this study also had DenysDrash syndrome, which on its own is a risk factor for chronic renal damage. The other patient with CKD had no associated congenital anomalies but received intensive treatment from relapse disease resulting in acute renal failure. A large study in 9162 children with Wilms tumor also revealed 173 cases (1.9%) of end-stage renal disease requiring renal replacement therapy. End-stage renal disease in 118 of these patients was due to CKD. Nearly half of this group had a WT1-associated congenital syndrome or anomaly. 18 In summary, long-term outcomes for children with renal tumor in Thailand may be less favorable, partly because of advance stage at presentation. Moreover, intensive therapy and acute renal complications still play major roles as risks for long-term renal impairment in these patients as well as associated congenital anomalies. These patients should be closely followed up long term for renal function impairment.
